Stock AMBU B AMBU A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ambu A/S

Equities

AMBU B

DK0060946788

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe
Other stock markets
 04:28:20 27/06/2024 pm IST 		5-day change 1st Jan Change
133.1 DKK -1.86% Intraday chart for Ambu A/S -2.38% +26.90%
21/06 Ambu A/S(CPSE:AMBU B) dropped from OMX Copenhagen 20 Index CI
15/05 Nordic Shares Moved Upward Wednesday; BioArctic Series B Topped Leaders DJ

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 27,812 44,622 48,168 16,876 19,669 36,124 - -
Enterprise Value (EV) 1 28,847 45,975 48,927 18,534 20,096 36,293 35,859 35,449
P/E ratio 88.7 x 186 x 194 x 180 x 115 x 75.1 x 55.7 x 41.7 x
Yield 0.33% 0.16% 0.15% - - 0.19% 0.27% 0.42%
Capitalization / Revenue 9.86 x 12.5 x 12 x 3.8 x 4.12 x 6.69 x 5.93 x 5.24 x
EV / Revenue 10.2 x 12.9 x 12.2 x 4.17 x 4.21 x 6.73 x 5.89 x 5.14 x
EV / EBITDA 49 x 75.5 x 88 x 43.8 x 31.8 x 35.4 x 28.4 x 22.6 x
EV / FCF 105 x -346 x -203 x -40.5 x 105 x 87.8 x 72.7 x 54.5 x
FCF Yield 0.95% -0.29% -0.49% -2.47% 0.96% 1.14% 1.38% 1.83%
Price to Book 12.6 x 18.8 x 12.2 x 3.91 x 3.69 x 6.2 x 5.67 x 5.12 x
Nbr of stocks (in thousands) 2,45,042 2,47,902 2,53,717 2,54,074 2,66,302 2,66,302 - -
Reference price 2 113.5 180.0 189.8 66.42 73.86 135.6 135.6 135.6
Announcement Date 13/11/19 11/11/20 09/11/21 15/11/22 08/11/23 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,820 3,567 4,013 4,444 4,775 5,397 6,088 6,898
EBITDA 1 589 609 556 423 632 1,025 1,261 1,567
EBIT 1 480 428 340 122 302 653.9 858.8 1,125
Operating Margin 17.02% 12% 8.47% 2.75% 6.32% 12.12% 14.11% 16.3%
Earnings before Tax (EBT) 1 413 322 308 109 210 623.9 839.5 1,115
Net income 1 317 241 247 93 168 480.9 650.5 868.1
Net margin 11.24% 6.76% 6.15% 2.09% 3.52% 8.91% 10.69% 12.58%
EPS 2 1.280 0.9700 0.9800 0.3700 0.6400 1.806 2.437 3.254
Free Cash Flow 1 274 -133 -241 -458 192 413.5 493.5 650.2
FCF margin 9.72% -3.73% -6.01% -10.31% 4.02% 7.66% 8.11% 9.43%
FCF Conversion (EBITDA) 46.52% - - - 30.38% 40.32% 39.13% 41.51%
FCF Conversion (Net income) 86.44% - - - 114.29% 85.98% 75.86% 74.91%
Dividend per Share 2 0.3800 0.2900 0.2900 - - 0.2578 0.3634 0.5643
Announcement Date 13/11/19 11/11/20 09/11/21 15/11/22 08/11/23 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1,031 1,122 1,128 1,163 1,132 1,189 1,195 1,259 1,254 1,367 1,357 1,425
EBITDA 1 102 125 119 77 145 125 173 189 213 285 245 255
EBIT 1 40 47 42 -7 68 46 91 97 126 194 157 166
Operating Margin 3.88% 4.19% 3.72% -0.6% 6.01% 3.87% 7.62% 7.7% 10.05% 14.19% 11.57% 11.65%
Earnings before Tax (EBT) 1 25 182 34 -132 28 19 63 100 120 187 154 163
Net income 1 20 175 28 -130 22 15 51 80 92 144 119 127
Net margin 1.94% 15.6% 2.48% -11.18% 1.94% 1.26% 4.27% 6.35% 7.34% 10.53% 8.77% 8.91%
EPS 2 0.0800 0.6900 0.1100 -0.5100 0.0900 0.0600 0.1900 0.3000 0.3500 0.5400 0.4500 0.4700
Dividend per Share - - - - - - - - - - - -
Announcement Date 08/02/22 05/05/22 25/08/22 15/11/22 07/02/23 03/05/23 31/08/23 08/11/23 30/01/24 14/05/24 - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,035 1,353 759 1,658 427 169 - -
Net Cash position 1 - - - - - - 265 675
Leverage (Debt/EBITDA) 1.757 x 2.222 x 1.365 x 3.92 x 0.6756 x 0.1651 x - -
Free Cash Flow 1 274 -133 -241 -458 192 414 494 650
ROE (net income / shareholders' equity) 16% 10.6% 7.81% 2% 3% 8.58% 10.6% 12.8%
ROA (Net income/ Total Assets) 7.21% 5.08% 4.63% 1.44% 2.39% 6.58% 8.71% 10.8%
Assets 1 4,396 4,742 5,333 6,478 7,037 7,305 7,468 8,074
Book Value Per Share 2 9.000 9.570 15.60 17.00 20.00 21.90 23.90 26.50
Cash Flow per Share 2 2.120 1.190 1.300 0.3700 1.920 2.800 3.400 4.100
Capex 1 259 428 569 553 326 363 430 468
Capex / Sales 9.18% 12% 14.18% 12.44% 6.83% 6.73% 7.06% 6.78%
Announcement Date 13/11/19 11/11/20 09/11/21 15/11/22 08/11/23 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ambu A/S

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
135.6 DKK
Average target price
113.8 DKK
Spread / Average Target
-16.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
AMBU A/S Stock Ambu A/S
+26.90% 5.17B
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.72% 182B
MEDTRONIC PLC Stock Medtronic plc
-2.83% 103B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.01% 66.94B
CENCORA, INC. Stock Cencora, Inc.
+15.53% 46.73B
DEXCOM, INC. Stock DexCom, Inc.
-8.53% 45.14B
HOYA CORPORATION Stock Hoya Corporation
+5.82% 41.57B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+17.67% 30.48B
TERUMO CORPORATION Stock Terumo Corporation
+14.00% 24.26B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.08% 23.58B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. AMBU B Stock
  4. Financials Ambu A/S